Aquestive Q1 net income $8.1M vs loss; raises FY revenue guidance to $42-46M

Aquestive Therapeutics, Inc.

2023-Q1 EPS reported $0.11 revenue$11,134,000

Net income $8.1M ($0.11 diluted EPS) vs net loss $13.2M ($0.32 loss) in Q1 2022.
Total revenue $11.1M, down from $12.3M YoY; excluding prior Sympazan sales, revenue +10%.
Non-GAAP adjusted EBITDA loss improved to $3.9M from $8.1M.
Raises FY2023 guidance: revenue $42-46M (prev. $37-41M); adj EBITDA loss $24-28M (prev. $31-36M).
Two shareholder lawsuits dismissed with prejudice in April 2023; brand name Anaphylm conditionally accepted by FDA.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Aquestive Therapeutics, Inc. updated its first quarter ended March 31, 2023 guidance (raised).

Period: first quarter ended March 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On May 2, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.

View on SEC.gov

Browse all earnings releases →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-014914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.